Related Experiment Video
Updated: Jul 17, 2026
09:19
Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model
Published on: September 20, 2020
N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular
Y Nishida1, S Minatoguchi, M Arai
1Second Department of Internal Medicine, Gifu University School of Medicine, Japan.
Heart and Vessels
|January 5, 2002
Summary
Pharmacological inhibition of glycogenolysis using N-methyl-1-deoxynojirimycin (MOR-14) protects the heart from postischemic dysfunction. Preischemic treatment with MOR-14 preserves cardiac function and glycogen content during ischemia.
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Background:
- Postischemic left ventricular dysfunction remains a significant clinical challenge.
- Glycogenolysis plays a critical role in myocardial energy metabolism during ischemia.
- Targeting glycogenolysis presents a potential therapeutic strategy for cardioprotection.
Purpose of the Study:
- To investigate the cardioprotective effects of N-methyl-1-deoxynojirimycin (MOR-14), a novel inhibitor of glycogenolysis.
- To determine if MOR-14 can mitigate left ventricular dysfunction following ischemia-reperfusion injury.
- To assess the impact of MOR-14 on myocardial glycogen content and lactate accumulation during ischemia.
Main Methods:
- Isolated rat hearts were perfused using a Langendorff apparatus.
- Hearts underwent a 30-minute global ischemia followed by 60 minutes of reperfusion.
- N-methyl-1-deoxynojirimycin (MOR-14) was administered at varying concentrations (0.5 or 2 mM) during the preischemic period or reperfusion.
- Left ventricular developed pressure (LVDP) and +/-dP/dt were continuously monitored.
- Myocardial glycogen and lactate content were measured during ischemia.
Main Results:
- Preischemic treatment with MOR-14 significantly improved LVDP and +/-dP/dt in a dose-dependent manner.
- Postischemic treatment did not confer significant protection.
- MOR-14 treatment preserved myocardial glycogen content and attenuated lactate accumulation during ischemia.
- Coronary flow was not significantly altered by MOR-14 treatment.
Conclusions:
- Preischemic administration of MOR-14 provides significant cardioprotection against postischemic left ventricular dysfunction.
- Inhibition of glycogenolysis by MOR-14 is a viable mechanism for protecting the heart during ischemia.
- MOR-14 represents a promising therapeutic agent for preventing ischemia-reperfusion injury.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...